Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 platelet inhibitor. It prevents the activation of platelets by blocking the binding of adenosine diphosphate (ADP) to its P2Y12 receptor.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** In combination with aspirin, for the prevention of thrombotic cardiovascular events in patients with ACS, including unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).
* **Myocardial Infarction (MI):** In patients who have had a myocardial infarction more than 1 year prior, to reduce the rate of cardiovascular death, MI, and stroke through combination with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **Duration:** Typically continued for at least 12 months, or longer in select patients, in combination with aspirin.
* **Post-MI (≥ 1 year prior):**
* **Maintenance Dose:** 60 mg orally twice daily.
* **Duration:** Typically continued for up to 3 years.
## Pediatric Dosing
No established pediatric dosing.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment needed for mild to moderate hepatic impairment. Caution is advised in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment needed for mild to severe renal impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* History of intracranial hemorrhage.
## Adverse Effects
* **Common:** Dyspnea, bleeding (including fatal and serious bleeding), bruising.
* **Serious:** Major bleeding, bradycardia, ventricular pauses, gout, hyperuricemia.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **Aspirin:** Should be used concurrently unless specifically contraindicated.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution.
* **Proton Pump Inhibitors (PPIs):** Some data suggest potential for reduced efficacy, particularly with omeprazole and esomeprazole, due to CYP2C19 inhibition. The clinical significance is uncertain.
## Monitoring
* Signs and symptoms of bleeding.
* Complete blood count (CBC), especially in patients with risk factors for bleeding or during prolonged treatment.
* Uric acid levels may be monitored periodically.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel, which is irreversible. This may lead to a faster offset of platelet inhibition if discontinuation is required.
* Patients on ticagrelor should avoid high-dose aspirin (e.g., aspirin > 100 mg daily) except in specific indications such as STEMI management.
* Dyspnea is a common side effect and is usually mild and transient, not requiring discontinuation.
* Management of bleeding should follow standard protocols. Discontinuation of ticagrelor and aspirin may be necessary depending on the severity.
***
*This information is intended for educational purposes and does not substitute for professional medical advice. Always verify current prescribing information with the official product labeling or a reliable drug reference.*
